Celsense, a Pittsburgh-based MRI biotechnology start-up firm, has received a $100,000 investment from the Pittsburgh Life Sciences Greenhouse (PLSG), a private/public partnership investing in the region’s life sciences industry. The company was founded in 2005 to commercialize imaging platforms licensed exclusively from Carnegie Mellon University.

The PLSG's investment in Celsense will be used to help the company further the commercialization of Cell Sense, its flagship product. Cell Sense is an MRI tracer agent that labels cells in culture. When labeled cells are transferred to a living subject, the transplanted cells can be imaged in their anatomical context using MRI.